Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Core Insights - Tevogen Bio Holdings Inc. emphasizes its biopharma model focused on sustainability and patient affordability, aiming to make precision medicine accessible to all [1] - The company is developing T cell therapies that are off-the-shelf, well-tolerated, and affordable, with a focus on cancers, neurologic diseases, and viral infections, particularly targeting Long COVID [2][2] - Tevogen values its first clinical product, TVGN 489, at $9–$11 billion rNPV, with projected 5-year top-line revenue of approximately $6.5 billion for liver cancer prevention related to chronic Hepatitis B [7] Recent Financial Announcements - Tevogen's financial outlook includes significant revenue projections from its product pipeline, particularly in the context of addressing high-risk chronic Hepatitis B infections [7] Recent Artificial Intelligence Announcements - Tevogen.AI has completed the alpha phase and begun beta build of its proprietary PredicTcell™ model in collaboration with Microsoft and Databricks, which is expected to drastically reduce target analysis time and save billions in drug development costs [7] - The company has received an international patent publication for its AI technology that predicts immunologically active peptides [7] Recent Corporate Announcements - Tevogen has received multiple patents related to Covid-19 and viral infections, enhancing its intellectual property portfolio [5][6] - A dedicated contact channel for Long COVID inquiries has been established, reflecting the global demand for effective solutions [7]